Literature DB >> 2039338

Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients.

M A Jenike1, L Baer, T Ballantine, R L Martuza, S Tynes, I Giriunas, M L Buttolph, N H Cassem.   

Abstract

To evaluate the feasibility of cingulotomy as a treatment for patients with intractable obsessive-compulsive disorder, we evaluated the records of all 35 patients with this diagnosis who had undergone one or more such procedures at Massachusetts General Hospital, Boston, during the last 25 years. Retrospectively, all but two of these patients met DSM-III-R criteria for obsessive-compulsive disorder. Six patients were deceased; four by suicide. Questionnaires were sent to the remaining 27 patients with obsessive-compulsive disorder; 17 patients returned the questionnaire and another agreed to an interview without completing the forms. Sixteen of these 18 patients participated in a telephone interview, and patient reports were corroborated by an informant in 10 cases. Despite the presence of some side effects, such as easily controlled seizures (9%) and transient mania (6%), the results of this investigation support the use of cingulotomy as a potentially effective treatment for patients with severe and disabling obsessive-compulsive disorder. With the use of very conservative criteria, we estimated that at least 25% to 30% of the patients benefited substantially from this procedure. Similar results were found in a preliminary prospective study of four patients who recently underwent cingulotomy after state-of-the-art preoperative treatments had failed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039338     DOI: 10.1001/archpsyc.1991.01810300060009

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  15 in total

Review 1.  Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Authors:  Jeremy D Schmahmann; Eric E Smith; Florian S Eichler; Christopher M Filley
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 2.  Neuromodulation for obsessive-compulsive disorder.

Authors:  Kyle A B Lapidus; Emily R Stern; Heather A Berlin; Wayne K Goodman
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

Review 3.  Pediatric indications for deep brain stimulation.

Authors:  Matthew F DiFrancesco; Casey H Halpern; Howard H Hurtig; Gordon H Baltuch; Gregory G Heuer
Journal:  Childs Nerv Syst       Date:  2012-07-25       Impact factor: 1.475

4.  Dissociation between MEG alpha modulation and performance accuracy on visual working memory task in obsessive compulsive disorder.

Authors:  Kristina T Ciesielski; Matti S Hämäläinen; Daniel A Geller; Sabine Wilhelm; Timothy E Goldsmith; Seppo P Ahlfors
Journal:  Hum Brain Mapp       Date:  2007-12       Impact factor: 5.038

Review 5.  Deep brain stimulation for psychiatric diseases: what are the risks?

Authors:  Christian Saleh; Denys Fontaine
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

Review 6.  The prefrontal cortex and neurosurgical treatment for intractable OCD.

Authors:  Steven A Rasmussen; Wayne K Goodman
Journal:  Neuropsychopharmacology       Date:  2021-08-25       Impact factor: 7.853

Review 7.  Treatment of obsessive-compulsive disorder in children and adolescents. A review of the literature.

Authors:  P H Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  1996-06       Impact factor: 4.785

Review 8.  Deep brain stimulation for the treatment of severe, medically refractory obsessive-compulsive disorder.

Authors:  Mark Sedrak; William Wong; Paul Wilson; Diana Bruce; Ivan Bernstein; Suketu Khandhar; Conrad Pappas; Gary Heit; Eric Sabelman
Journal:  Perm J       Date:  2013

9.  Functional neurosurgery in the treatment of severe obsessive compulsive disorder and major depression: overview of disease circuits and therapeutic targeting for the clinician.

Authors:  Dhwani B Shah; Angeliki Pesiridou; Gordon H Baltuch; Donald A Malone; John P O'Reardon
Journal:  Psychiatry (Edgmont)       Date:  2008-09

10.  Nonpharmacological treatments for anxiety disorders.

Authors:  Jean Cottraux
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.